Overview

Pinaverium Bromide Preventing Post Extracorporeal Shock Wave Lithotripsy Pancreatitis and Painful (PBPEP)

Status:
ENROLLING_BY_INVITATION
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
This study aims to evaluate whether perioperative pinaverium bromide (a calcium antagonist) reduces post-ESWL complications (pancreatitis, abdominal pain, infection) in chronic pancreatitis patients with pancreatic duct stones 5mm. A single-center, randomized, double-blind, placebo-controlled design will be used, with 288 participants allocated to either pinaverium bromide (100mg tid) or placebo before and after p-ESWL.
Phase:
NA
Details
Lead Sponsor:
Yanqing Li
Treatments:
Control Groups
pinaverium